<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04017572</url>
  </required_header>
  <id_info>
    <org_study_id>PCT171447</org_study_id>
    <nct_id>NCT04017572</nct_id>
  </id_info>
  <brief_title>Optimized vs. Standard Automated Peritoneal Dialysis Regimens Study</brief_title>
  <acronym>OptiStAR</acronym>
  <official_title>Optimized vs. Standard Automated Peritoneal Dialysis Regimens (OptiStAR): A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lund University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universidad de Córdoba</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Lund University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical study is designed to evaluate the theoretical prediction of a lower glucose&#xD;
      absorption in optimized automated peritoneal dialysis regimes. Patients will receive both a&#xD;
      standard 6 x 2L 1.36% glucose regime or an optimized 7 x 2 L 2.27% glucose + 5 x 2 L 0.1%&#xD;
      glucose regime in a crossover fashion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Automated peritoneal dialysis (APD) is a rapidly growing, home-based kidney replacement&#xD;
      therapy promoting patient autonomy, and is associated with lower societal costs compared to&#xD;
      hemodialysis. However, in light of the growing number of diabetic patients on PD, the&#xD;
      unwanted glucose absorption during APD is problematic. Recent results (Öberg CM, Rippe B,&#xD;
      2017, see references), using a theoretical model of APD, indicate that large reductions in&#xD;
      glucose absorption are possible by using specialized so-called optimized bi-modal treatment&#xD;
      regimes having &quot;UF cycles&quot; using a higher glucose concentration (e.g. 2.27% glucose) and&#xD;
      &quot;Clearance cycles&quot; using a low glucose concentration (e.g. 0.1% glucose).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Actual">September 30, 2020</completion_date>
  <primary_completion_date type="Actual">September 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucose absorption</measure>
    <time_frame>Through study completion, up to 1 year</time_frame>
    <description>Amount of glucose absorbed across the peritoneal membrane during the treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ultrafiltration</measure>
    <time_frame>Through study completion, up to 1 year</time_frame>
    <description>Amount of water transported from the circulation to the peritoneal cavity during the treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine clearance</measure>
    <time_frame>Through study completion, up to 1 year</time_frame>
    <description>Amount of creatinine transported from the circulation to the peritoneal cavity during the treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urea clearance</measure>
    <time_frame>Through study completion, up to 1 year</time_frame>
    <description>Amount of urea transported from the circulation to the peritoneal cavity during the treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sodium removal</measure>
    <time_frame>Through study completion, up to 1 year</time_frame>
    <description>Amount of sodium transported from the circulation to the peritoneal cavity during the treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of complications</measure>
    <time_frame>Up to 14 days post-intervention</time_frame>
    <description>Complications that are or can be suspected to be related to the study intervention</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>End Stage Kidney Disease</condition>
  <condition>Chronic Kidney Disease Requiring Chronic Dialysis</condition>
  <arm_group>
    <arm_group_label>Standard treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>APD-treatment with a net volume of 12 L 1.36 % anhydrous glucose peritoneal dialysis solution during 540 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Optimized treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>APD-treatment with a net volume of 14 L 2.27 % anhydrous glucose peritoneal dialysis solution during 280 minutes followed by a net volume of 10 L 0.1 % glucose dialysis fluid during 200 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Automated peritoneal dialysis (APD)</intervention_name>
    <description>Automated peritoneal dialysis (APD) using the Baxter HomeChoice Pro Cycler.</description>
    <arm_group_label>Optimized treatment</arm_group_label>
    <arm_group_label>Standard treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age between 18 and 75 years;&#xD;
&#xD;
          -  duration of PD (automated peritoneal dialysis (APD) or continuous ambulatory&#xD;
             peritoneal dialysis (CAPD)) &gt;4 weeks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  severe heart failure (New York Heart Association Functional Classification; NYHA III&#xD;
             or IV);&#xD;
&#xD;
          -  pregnancy;&#xD;
&#xD;
          -  catheter malfunction or&#xD;
&#xD;
          -  peritonitis within 3 months prior to the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carl M Öberg, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lund University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Privado Centro Médico de Córdoba</name>
      <address>
        <city>Córdoba</city>
        <zip>5016</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <reference>
    <citation>Öberg CM, Rippe B. Optimizing Automated Peritoneal Dialysis Using an Extended 3-Pore Model. Kidney Int Rep. 2017 Apr 27;2(5):943-951. doi: 10.1016/j.ekir.2017.04.010. eCollection 2017 Sep.</citation>
    <PMID>29270500</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>July 4, 2019</study_first_submitted>
  <study_first_submitted_qc>July 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2019</study_first_posted>
  <last_update_submitted>February 10, 2021</last_update_submitted>
  <last_update_submitted_qc>February 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dialysis</keyword>
  <keyword>peritoneal dialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

